5:43 PM
 | 
Mar 25, 2013
 |  BC Extra  |  Company News

Second complete response for United's oral treprostinil

FDA issued a complete response letter for a resubmitted NDA from United Therapeutics Corp. (NASDAQ:UTHR) for oral treprostinil to treat pulmonary arterial hypertension (PAH). The company declined to disclose details of the letter, but said the agency did...

Read the full 175 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >